{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Brandon R"],"funding":["Maurice Wilkins Centre for Molecular Biodiscovery","Health Research Council of New Zealand"],"pubmed_abstract":["<h4>Background</h4>Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.<h4>Aims</h4>We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of Māori/Pacific ethnicity, and those with obesity and/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).<h4>Methods</h4>A randomised, open-label, two-period crossover trial was conducted in New Zealand. Adults with type 2 diabetes, HbA1c>58mmol/mol (>7.5%), received 16 weeks of either pioglitazone (30mg) or vildagliptin (50mg) dail"],"journal":["Frontiers in endocrinology"],"pagination":["1091421"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9869378"],"repository":["biostudies-literature"],"pubmed_title":["Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial."],"pmcid":["PMC9869378"],"pubmed_authors":["Merry T","Smallman K","Shepherd PR","Nehren N","Tweedie-Cullen R","Brandon R","King F","Paul R","Merriman TR","Jiang Y","Doran RJ","Orr-Walker B","Yeu RQ","Macaskill-Smith KA","Hindmarsh JH","Moffitt A","Doherty G","Clark P","Leask MP","Murphy R"],"additional_accession":[]},"is_claimable":false,"name":"Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.","description":"<h4>Background</h4>Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.<h4>Aims</h4>We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of Māori/Pacific ethnicity, and those with obesity and/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).<h4>Methods</h4>A randomised, open-label, two-period crossover trial was conducted in New Zealand. Adults with type 2 diabetes, HbA1c>58mmol/mol (>7.5%), received 16 weeks of either pioglitazone (30mg) or vildagliptin (50mg) dail","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-28T03:41:12.85Z","creation":"2025-04-05T21:07:37.168Z"},"accession":"S-EPMC9869378","cross_references":{"pubmed":["36699039"],"doi":["10.3389/fendo.2022.1091421"]}}